FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* $\underline{Pascoe\ Richard\ W}$					2. Issuer Name and Ticker or Trading Symbol KEMPHARM, INC [ KMPH ]							ck all applica	,	son(s) to Issu 10% Ov		
	MPHARM	, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/24/2016							Officer ( below)	give title	Other (s below)	specify	
2656 CROSSPARK ROAD, SUITE 100				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CORALVILLE IA 52241											) Line	'				
(City)	(:	State)	(Zip)													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				Transaction ate Month/Day/	Execution D		Date, Transaction Code (Instr.					5. Amoun Securities Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code V	Amount	(A) or (D)	Price	Transaction (Instr. 3 and	on(s) nd 4)		(IIISU. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		ate Execution Date,	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (right to buy)	\$6.05 <sup>(1)</sup>	05/24/2016		A		10,000 <sup>(2)</sup>		(3)	05/23/2026	Common Stock	10,000	\$0.00	10,000	D		

## **Explanation of Responses:**

- 1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 24, 2016.
- 2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy.
- 3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

## Remarks:

/s/ Matthew P. Dubofsky, Attorney-in-Fact for Richard W. 05/26/2016 Pascoe

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.